Benzbromarone Therapy in Treatment-Resistant Gout

Title: Benzbromarone therapy in management of refractory gout.
Kumar S, et al.
Publication: N Z Med J. 2005 Jun 24;118(1217):U1528.

In this study, the authors wanted to assess the efficacy and safety of benzbromarone medication in patients with kidney conditions and severe gout with uric acid crytal deposits.

They enrolled 6 patients with gout that have resisted conventional treatment in this study, and gave them benzbromarone. After 1 year of treatment, the average uric acid level was reduced by approximately 25% from 0.61 mmol/L to 0.46 mmol/L. The frequency of acute gout attack was also reduced from 16 (an average of the span of 8 to 20 times affecting these patients) to 7.3 (the average of a span of 1 o 16). Non patients reported adverse side effects with benzbromarone and no acute gout flares resulted when the medicines were first administered.

The authors concluded that benzbromarone is effective in reducing uric acid levels and the number of gout attacks in patients that failed to respond to conventional treatments.

Editor’s note: benzbromarone is a uricosuric agent, which can lower uric acid levels in people with hyperuricemia (high levels of uric acid in the blood) and gout.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Gout Overview
Food to Avoid
Research Summaries
Web Resources

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English